Non-Diabetic Nephropathy - Use of ACE Inhibitor or ARB Therapy

INACTIVE REVIEW: This measure review is older than five years.

The percentage of patients aged 18 years and older with proteinuria who are taking an ACE inhibitor or ARB

Date Reviewed: November 23, 2013
Do Not Support
    Health Plan Population: Regional and State

Measure Info

NQF 0621 NQF Endorsement Removed
Measure Type
Process
Measure Steward
ActiveHealth Management
Clinical Topic Area
Chronic Kidney Disease
Care Setting
Outpatient
Data Source
Claims
Electronic Health Records
Instrument-Based Data

ACP does not support NQF 0621: “Non-Diabetic Nephropathy - Use of ACE Inhibitor or ARB Therapy.” While the clinical reasoning underlying the measure is sound, it does not reflect the most recent Kidney Disease | Improving Global Outcomes (KDIGO) guidelines on the management of CKD. Cut-points in the denominator and exclusion criteria should be updated to align with current recommended practice standards. Specifically, KDIGO recommends an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) for diabetic CKD patients with albumin excretion of 30-300 mg/24 hours, and for patients with albumin excretion greater than 300 mg/24 hours, regardless of diabetes status. The division of stage 3 CKD into stages 3a (GFR 45-59 ml/min/1.73 m2) and 3b (GFR 30-44 ml/min/1.73 m2) should also be noted explicitly in the exclusion criteria along with guidance as to whether both patient populations should be excluded.